First Nebraska Trust Co Makes New $2.03 Million Investment in Thermo Fisher Scientific Inc. $TMO

First Nebraska Trust Co acquired a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 3,006 shares of the medical research company’s stock, valued at approximately $2,029,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. BlackRock Inc. purchased a new position in shares of Thermo Fisher Scientific in the 2nd quarter worth $15,501,867,000. Corient Private Wealth LP acquired a new position in Thermo Fisher Scientific in the second quarter valued at $382,547,000. Bank of New York Mellon Corp purchased a new stake in Thermo Fisher Scientific during the second quarter valued at about $1,974,561,000. Bank of America Corp DE purchased a new stake in Thermo Fisher Scientific during the second quarter valued at about $1,952,930,000. Finally, Legal & General Group Plc acquired a new stake in Thermo Fisher Scientific during the second quarter worth about $1,122,351,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

TMO has been the topic of a number of research reports. Jefferies Financial Group restated a “buy” rating and issued a $630.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday, July 23rd. Stifel Nicolaus boosted their target price on Thermo Fisher Scientific from $650.00 to $775.00 and gave the stock a “buy” rating in a report on Thursday, October 22nd. UBS Group reiterated a “buy” rating and set a $800.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, October 22nd. Piper Sandler assumed coverage on shares of Thermo Fisher Scientific in a research report on Wednesday, September 9th. They set an “overweight” rating for the company. Finally, Guggenheim began coverage on shares of Thermo Fisher Scientific in a report on Thursday, October 15th. They issued a “buy” rating on the stock. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $689.10.

Insider Buying and Selling

In related news, CAO Joseph R. Holmes sold 420 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the transaction, the chief accounting officer directly owned 2,966 shares of the company’s stock, valued at approximately $1,734,546.46. The trade was a 12.40% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Lisa P. Britt sold 2,831 shares of the business’s stock in a transaction that occurred on Wednesday, October 28th. The stock was sold at an average price of $706.45, for a total value of $1,999,959.95. Following the transaction, the vice president directly owned 11,560 shares in the company, valued at $8,166,562. This trade represents a 19.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 76,199 shares of company stock worth $45,896,780 over the last three months. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Stock Up 2.3%

Shares of Thermo Fisher Scientific stock opened at $698.24 on Wednesday. The company has a fifty day moving average price of $657.33 and a 200 day moving average price of $553.71. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.71. Thermo Fisher Scientific Inc. has a twelve month low of $435.27 and a twelve month high of $711.85. The stock has a market cap of $258.71 billion, a price-to-earnings ratio of 36.83, a price-to-earnings-growth ratio of 2.78 and a beta of 0.84.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, October 21st. The medical research company reported $6.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $0.28. Thermo Fisher Scientific had a return on equity of 17.33% and a net margin of 14.94%. The firm had revenue of $12.14 billion during the quarter, compared to the consensus estimate of $11.95 billion. During the same period in the prior year, the firm earned $5.79 EPS. The firm’s quarterly revenue was up 9.1% compared to the same quarter last year. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 25.26 earnings per share for the current fiscal year.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.